Abstract Body

Background: Variability in antiretroviral pharmacokinetics is influenced by numerous factors affecting absorption, distribution, metabolism and elimination. Recently, a relative genetic contribution (rGC) of 0.904 (0.64 – 0.97) was reported for nevirapine (NVP) AUC0-6h (Micheli et al, Pharmacogenet Genomics, 2013). The aim of this study was to assess the rGC of a panel of antiretroviral drugs to assess the degree by which heritability influences their pharmacokinetics. Methodology: Patients from the Therapeutic Drug Monitoring Registries of the University of Turin and the University of Liverpool were included in the study. Inclusion criteria were as follows: receiving boosted lopinavir (LPV/r, 300/100 mg b.i.d.), boosted atazanavir (ATV/r 300/100 q.d.), unboosted ATV (ATV, 400mg q.d.), efavirenz (EFV, 600 mg q.d.), NVP (400 mg q.d.) or raltegravir (RAL, 400 mg b.i.d), age>18 years, not receiving drugs known to contribute to drug-drug interactions. Plasma drug concentrations were determined using HPLC or LC-MS/MS methods. Intrapatient (SDw) and interpatient (SDb) variability were measured in patients with Cmin or C12h available from more than one visit. The rGC was calculated using the following equation: 1-(1/F) where F= SDb2/SDw2. Statistical significance for genetic contribution was calculated using F-test, α = 0.05. Results: A total of 211 patients were included in the study. SDw and SDb were 38% and 43% for LPV/r (n = 37), 49% and 50% for ATV/r (n = 24), 54% and 104% for ATV (n = 24), 33% and 60% for EFV (n = 82), 19% and 44% for NVP (n = 20), and 81% and 95% for RAL (n = 24), respectively. Mean with 95% CI rGC was calculated to be 0.35 (0.06 – 0.55) for LPV/r, 0.15 (0 – 0.6) for ATV/r, 0.55 (0.35 – 0.7) for ATV, 0.78 (0.68 – 0.85) for EFV, 0.82 (0.62 – 0.91) for NVP and 0.08 (0 – 0.56) for RAL (Figure). Genetic contribution was statistically significant (p < 0.05) for ATV, EFV and NVP. All patients were of Caucasian ancestry and neither age nor gender was significantly associated with plasma concetrations for any drug. Conclusions: The rank order for genetic contribution to variability in PK for the study drugs was NVP > EFV > ATV > LPV/r > ATV/r > RAL indicating class-specific differences exist. Interestingly, these data indicate that ritonavir reduces the genetic contribution to variability in ATV concentrations presumably through inhibition of gene products such as CYP3A4 and ABCB1. Drugs with higher rGC scores may represent better candidates for pharmacogenetic studies.